RTP Mobile Logo

Sunday, June 3, 2018, Chicago, IL, 6:45 AM – 7:45 AM

Breakfast with the Investigators: New Agents and Strategies in the Management of Ovarian Cancer

Event Details

Location:
Hilton Chicago
720 South Michigan Avenue
Chicago, IL 60605
Hotel Phone: (312) 922-4400

Time:
6:15 AM – 6:45 AM (Central Time) — Registration
6:45 AM – 7:45 AM (Central Time) — Educational Breakfast Meeting

Meeting Room:
Grand Ballroom (Level 2)

There is no registration fee for this event. However, preregistration is advised as seating is limited.  
 
Faculty:
Robert L Coleman, MD
Professor and Vice Chair, Clinical Research
Ann Rife Cox Chair in Gynecology
Department of Gynecologic Oncology and Reproductive Medicine
The University of Texas MD Anderson Cancer Center
Houston, Texas

Ursula A Matulonis, MD
Medical Director and Program Leader
Gynecologic Oncology Program
Professor of Medicine
Harvard Medical School
Dana-Farber Cancer Institute
Boston, Massachusetts


Kathleen Moore, MD
Jim and Christy Everest Endowed Chair in Cancer Research
Director, Oklahoma TSET Phase I Program
Stephenson Cancer Center
Associate Professor, Section of Gynecologic Oncology
Director, Gynecologic Oncology Fellowship
Department of Obstetrics and Gynecology
University of Oklahoma Health Sciences Center
Oklahoma City, Oklahoma

Moderator:
Neil Love, MD
Research To Practice
Miami, Florida

Not an official event of the 2018 ASCO Annual Meeting. Not sponsored, endorsed, or accredited by ASCO, CancerLinQ, or the Conquer Cancer Foundation.

This activity is supported by educational grants from Clovis Oncology, ImmunoGen Inc, Merck and Tesaro Inc.

Agenda

Meeting Format and Agenda

This unique activity will feature several distinct content modules during which the faculty will review available data sets, present cases from their practices and provide perspectives on key clinical questions as part of a moderated discussion. The event will not include traditional didactic lectures, and the following topics will be reviewed.

MODULE 1: Genetic Testing in Ovarian Cancer (OC) and Biologic Basis for the Use of PARP Inhibitors

  • Frequency and clinical significance of germline and somatic BRCA mutations
  • Similarities and differences among available genetic testing platforms; role of extended panel testing/next-generation sequencing
  • Identification of “BRCA-like” and other genomic signatures (eg, HRD) that may predict benefit from PARP inhibition
  • Incidence and potential clinical relevance of other inherited mutations (eg, RAD51C, RAD51D, BRIP1)

MODULE 2: Management of Recurrent and Newly Diagnosed Advanced OC

  • Phase III data comparing the safety and efficacy of neoadjuvant systemic therapy versus up-front debulking surgery followed by adjuvant chemotherapy
  • Lingering controversies regarding the optimal dose, schedule and delivery of adjuvant chemotherapy in OC
  • Available research data with and current clinical role of bevacizumab as a component of up-front therapy for patients with newly diagnosed OC; impact of relapse risk on this decision
  • Clinical and biologic factors affecting the choice of therapy at first relapse: response to prior therapy, influence of comorbidities, BRCA status, residual side effects and patient preferences
  • Biologic rationale for maintenance therapy in patients with platinum-sensitive relapsed OC

MODULE 3: Integration of PARP Inhibitors into Current Treatment Algorithms; Novel Strategies Under Investigation

  • FDA indications for and optimal integration of niraparib, olaparib and rucaparib into contemporary OC treatment algorithms
  • Design, eligibility requirements and results from the Phase III NOVA (niraparib), SOLO-2 (olaparib) and ARIEL3 (rucaparib) trials evaluating PARP inhibition as maintenance therapy in patients with platinum-sensitive, recurrent OC
  • Stratification and related outcomes for various patient subsets (eg, BRCA mutation-positive, HRD-positive, wild-type) enrolled on Phase III PARP inhibitor maintenance trials
  • Toxicities associated with the use of available PARP inhibitors and strategies to prevent and/or ameliorate them; indications for the use of supportive care measures and/or treatment modifications/delays
  • Biologic rationale for, available data with and ongoing trials evaluating PARP inhibitors in earlier lines of therapy or combined with other agents (eg, immunotherapy, anti-angiogenics)

MODULE 4: Novel Investigational Agents and Strategies

  • Mechanism of action of mirvetuximab soravtansine and the biologic rationale for targeting the folate receptor in ovarian and other gynecologic cancers
  • Available safety and efficacy data with and active trials of mirvetuximab soravtansine for patients with OC
  • Biologic rationale for, available data with and ongoing evaluation of anti-PD-1/PD-L1 antibodies alone or in combination with other therapies for patients with OC
  • Other targeted agents (eg, WEE1 kinase inhibitors, CDK4/6 inhibitors) under investigation in OC

CE Information

Target Audience:
This activity is intended for medical oncologists, gynecologic oncologists and other healthcare providers involved in the treatment of ovarian cancer (OC).

Learning Objectives and Goals:
At the conclusion of this activity, participants should be able to:

  • Appraise available guideline recommendations and consensus statements regarding the indications for genetic testing in OC, and use the results of these assessments to guide long-term treatment planning.
  • Appreciate available clinical trial data with and approved indications for the use of FDA-approved PARP inhibitors for patients with OC in order to appropriately integrate these agents into routine clinical practice.
  • Recognize the toxicities associated with PARP inhibitors commonly used in the care of patients with OC, and offer supportive management strategies to minimize and/or ameliorate these side effects.
  • Recall the biologic rationale for and ongoing research efforts evaluating the role of PARP inhibitors in combination with chemotherapy, targeted therapy and immunotherapy, and refer appropriate patients for clinical trial participation.
  • Review the mechanisms of action, emerging efficacy data and toxicity profiles of novel targeted agents and immunotherapeutic approaches under investigation in OC, and effectively prioritize clinical trial opportunities for appropriate patients.

CME Credit Form:
A CME credit form will be given to each participant at the conclusion of the activity.

Accreditation Statement:
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation Statement:
Research To Practice designates this live activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure Policy:
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations. Financial disclosures will be provided in meeting course materials.

Supporters:
This activity is supported by educational grants from Clovis Oncology, ImmunoGen Inc, Merck and Tesaro Inc.

Location

Hilton Chicago
720 South Michigan Avenue
Chicago, IL 60605
Hotel Phone: (312) 922-4400

Meeting Room:
Grand Ballroom (Level 2)

Directions:
The Hilton Chicago hotel is located just 5 minutes (2.5 miles) north of the McCormick Place convention center.

 

Registration

This activity is intended for medical oncologists, gynecologic oncologists and other healthcare providers involved in the treatment of ovarian cancer.

There is no registration fee for this event. However, preregistration is advised as seating is limited.

Registration for clinicians in practice

I am a practicing physician, fellow, nurse or other healthcare provider involved in the treatment of cancer.

Registration for clinicians in practice »
 
Registration for other/industry professionals*

Please note, a limited number of seats are currently available for nonclinicians on a first come, first served basis.

Registration for other/industry professionals »

* Individuals employed by for-profit organizations, including financial institutions, biotech or pharmaceutical companies
Registration for groups
If you are registering a group (more than 1 person) for this event, please contact us at Meetings@ResearchToPractice.com or (800) 233-6153.
To ensure seating, please check in at our onsite registration desk at least 30 minutes before the start of the meeting. We cannot guarantee seating after the start of the program.

Meal service will be provided to those who attend the program, based on availability.

Photography and/or video recording may be taken during the educational program by Research To Practice and used in future educational programs.

Research To Practice fully complies with the legal requirements of the ADA. If you are in need of assistance (ie, physical, dietary, et cetera), please contact us prior to the event at (800) 233-6153.